VISION AND STRATEGY
Our goal is to provide innovative technologies that optimizes platin treatments, helping doctors focus on patients most likely to benefit, reducing toxicity and overtreatment
A different approach through Intelligent Oncology
Our mission is to revolutionize cancer care through research-driven, personalized therapies that are both safer and more effective. Traditional chemotherapies like cisplatin, though critical in treating various cancers, can suffer from high toxicity, limited response rates, and resistance, impacting patient quality of life and outcomes. Cisplatin is prescribed to 10–15% of cancer patients globally for cancers like lung, breast, bladder, and certain childhood cancers, yet not all patients benefit equally.
At CHOSA, we are the only company with a tool that can predict which patients will benefit from cisplatin treatment and which will not. This precision is critical for personalizing treatment plans and increasing the chances of successful outcomes. We work closely with leading specialists in lung, breast, bladder, head, and neck cancers to bring this life-saving tool to patients worldwide. Our technology further identifies patients who will benefit from the powerful combination of cisplatin and immune therapies, now a gold standard for several cancers, while sparing non-responders unnecessary side effects. By delivering the right treatment to the right patient, CHOSA is setting a new standard for precision medicine and working toward higher response rates
Our strategy is driven by our core values
Patient-centered innovation: We prioritize advancements that enhance response rates and minimize toxicity, improving both patient experience and outcomes.
Commitment to personalization: We believe in a future where treatment is as unique as each patient, focusing on tailored solutions that are both safe and effective.
Compassion and protection: Our commitment to safeguarding patients from ineffective treatments underlines our dedication to their well-being.
Excellence in combination therapy: By combining cisplatin and PD-(L)1 inhibitors, we are setting new standards for cancer treatment through innovative approaches.